S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
The Next Big Crisis Is Here (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
The Next Big Crisis Is Here (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
The Next Big Crisis Is Here (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
The Next Big Crisis Is Here (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
NASDAQ:BTAI

BioXcel Therapeutics - BTAI Stock Forecast, Price & News

$31.66
-0.35 (-1.09%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$31.54
▼
$32.48
50-Day Range
$14.49
▼
$32.73
52-Week Range
$8.80
▼
$32.96
Volume
192,193 shs
Average Volume
359,689 shs
Market Capitalization
$887.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.78

BioXcel Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
67.1% Upside
$52.89 Price Target
Short Interest
Bearish
12.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.13
Upright™ Environmental Score
News Sentiment
0.59mentions of BioXcel Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$3.07 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.37) to ($5.47) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

128th out of 1,055 stocks

Pharmaceutical Preparations Industry

50th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

BTAI stock logo

About BioXcel Therapeutics (NASDAQ:BTAI) Stock

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Stock News Headlines

January 27, 2023 | finance.yahoo.com
BTAI: Multiple Catalysts Ahead in 2023
January 27, 2023 | americanbankingnews.com
Frank Yocca Sells 50,000 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Stock
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 25, 2023 | americanbankingnews.com
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Average Rating of "Moderate Buy" from Brokerages
January 24, 2023 | americanbankingnews.com
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Up 10.1% in December
January 24, 2023 | americanbankingnews.com
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Update
January 19, 2023 | americanbankingnews.com
BioXcel Therapeutics (NASDAQ:BTAI) Trading Down 5.6%
January 13, 2023 | markets.businessinsider.com
Mizuho Securities Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI)
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 11, 2023 | markets.businessinsider.com
BioXcel Announces Promising Data From Phase 2 Trial Of BXCL701 Combination In Rare Prostate Cancer
January 11, 2023 | finance.yahoo.com
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
December 27, 2022 | finance.yahoo.com
A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy
December 22, 2022 | finance.yahoo.com
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
December 22, 2022 | finance.yahoo.com
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
December 19, 2022 | finance.yahoo.com
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
December 15, 2022 | finance.yahoo.com
Why BioXCel Therapeutics Stock Jumped This Week
December 3, 2022 | finance.yahoo.com
Why BioXcel Therapeutics Stock Triumphed This Week
December 1, 2022 | finance.yahoo.com
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
November 30, 2022 | finance.yahoo.com
BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia
November 18, 2022 | markets.businessinsider.com
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
November 14, 2022 | finance.yahoo.com
BTAI: Positive Early Metrics for IGALMI™ Launch…
November 14, 2022 | finance.yahoo.com
BioXcel Therapeutics to Present at Two Upcoming Investor Conferences
November 10, 2022 | seekingalpha.com
BioXcel stock soars 17% as lead drug Igalmi starts to bring in revenue
November 10, 2022 | finance.yahoo.com
BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
October 27, 2022 | finance.yahoo.com
BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
October 5, 2022 | finance.yahoo.com
BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022
September 14, 2022 | finance.yahoo.com
BioXcel Therapeutics, Inc. (BTAI)
See More Headlines
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Company Calendar

Last Earnings
11/10/2022
Today
1/27/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BTAI
CUSIP
N/A
CIK
1720893
Web
www.bioxceltherapeutics.com
Phone
(475) 238-6837
Fax
N/A
Employees
89
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.89
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+63.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-106,930,000.00
Net Margins
N/A
Pretax Margin
-100,052.56%
Return on Equity
-77.56%
Return on Assets
-58.11%

Debt

Debt-to-Equity Ratio
0.72
Current Ratio
10.34
Quick Ratio
10.28

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.92 per share
Price / Book
4.00

Miscellaneous

Outstanding Shares
28,022,000
Free Float
17,654,000
Market Cap
$887.18 million
Optionable
Not Optionable
Beta
1.16

Key Executives

  • Dr. Vimal D. Mehta Ph.D. (Age 62)
    Founder, CEO, Pres, & Director
    Comp: $1.41M
  • Dr. Frank D. Yocca Ph.D. (Age 67)
    Sr. VP & Chief Scientific Officer
    Comp: $452.58k
  • Mr. Javier Rodriguez (Age 51)
    Sr. VP, Chief Legal Officer & Corp. Sec.
    Comp: $470.53k
  • Dr. Krishnan Nandabalan Ph.D. (Age 60)
    Chief Digital Officer ?& Director
    Comp: $150k
  • Mr. Richard I. Steinhart MBA (Age 66)
    Sr. VP & CFO
  • Ms. Mary Coleman
    VP of Investment Relations
  • Dr. Iris Francesconi Ph.D.
    Sr. VP of Marketing, Market Research & Commercial Assessments
  • Dr. Vincent J. O'Neill M.D. (Age 54)
    B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer
  • Dr. Cedric Burg
    VP and Head of Global Clinical Operations & Project Management
  • Dr. Chetan D. Lathia Ph.D.
    Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BTAI Stock - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BTAI shares.
View BTAI analyst ratings or view top-rated stocks.

What is BioXcel Therapeutics' stock price forecast for 2023?

8 analysts have issued twelve-month price objectives for BioXcel Therapeutics' shares. Their BTAI share price forecasts range from $24.00 to $80.00. On average, they predict the company's stock price to reach $52.89 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price.
View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts.

How have BTAI shares performed in 2023?

BioXcel Therapeutics' stock was trading at $21.48 at the beginning of the year. Since then, BTAI stock has increased by 47.4% and is now trading at $31.66.
View the best growth stocks for 2023 here.

When is BioXcel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our BTAI earnings forecast.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings results on Thursday, November, 10th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.34) by $0.15. The firm earned $0.14 million during the quarter, compared to analysts' expectations of $3.05 million.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Artemis Investment Management LLP (4.76%), DAVENPORT & Co LLC (0.56%) and Hennion & Walsh Asset Management Inc. (0.14%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Krishnan Nandabalan, Vimal Mehta and Vincent O'neill.
View institutional ownership trends.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $31.66.

How much money does BioXcel Therapeutics make?

BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $887.18 million. The company earns $-106,930,000.00 in net income (profit) each year or ($4.89) on an earnings per share basis.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com.

This page (NASDAQ:BTAI) was last updated on 1/28/2023 by MarketBeat.com Staff